We are constantly evaluating pipeline expansion opportunities that leverage our knowledge of MASH and FGF21.
We are committed to expanding our pipeline with high-quality assets that complement our flagship EFX asset. Compelling science governs our evaluations, with an emphasis on assets that complement EFX’s therapeutic profile as a potential therapy for MASH. We also continually evaluate the potential for EFX to be developed for patients with other serious metabolic diseases.
![PSB_Image_4](https://akerotx.com/wp-content/uploads/2021/09/PSB_Image_4.jpg)